Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for rare diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It also develops Next Gen ERT for the treatment of OPLL (Ossification of the Posterior Longitudinal Ligament); and Gene therapy, a disease of the PPi-Adenosine Pathway. The company has license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.